Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine Acquires Satoris Biomarker IP

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine today said that it has acquired intellectual property assets covering biomarker technology from Satoris.

The deal includes biomarkers and biomarker panels for clinical research use for Alzheimer's disease, frontal temporal dementia, Parkinson's disease, and other central nervous system conditions.

Two years ago, Redwood City, Calif.-based Satoris had signed an agreement to distribute RBM's DiscoveryMAP panel for neurology research. It also sells its own Dementia Discrimination panel, which it said is used to differentiate Alzheimer's patients from patients with other forms of dementia.

"These assets from Satoris will be an important contributor as we continue to develop research and diagnostic offerings for neurodegenerative illnesses which affect millions of individuals and families," Craig Benson, president and CEO of Rules-Based Medicine, said in a statement.

Financial terms of the agreement were not disclosed.

Austin, Texas-based RBM agreed last month to be acquired by Myriad Genetics for $80 million.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.